Onyx Pharmaceuticals Completes Enrollment in ASPIRE Phase 3 Carfilzomib Combination Trial for the Potential Treatment of Relapsed Multiple Myeloma

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has reached the target enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma.

The company has an agreement with the U.S. Food and Drug Administration for a Special Protocol Assessment and has received Scientific Advice from the European Medicines Agency on the design and planned analysis of the ASPIRE trial.